Int J Clin Oncol: Safe and effective ness of carplatinum or cytoxisia monotomatherapy for local advanced head and neck cancer patients who cannot receive cisplatin treatment

Head and neck local late-stage squamous cell carcinoma (LASCCHN) usually uses cisplatin-based radiotherapy unless the patient is elderly or has kidney, heart, or nerve dysfunctionThis study compared the safety and effectiveness of using both calplatin (CBDCA) and cytoxiformer monoab (CMab) plus radiotherapy (RT) in patients who did not qualify for CDDP treatmentwe reviewed the treatment of MSCCCHN patients in two Japanese institutions between August 2006 and December 2015 who received CBDCA plus RT (n s 29) or Cmab plus RT (n s 18) for non-qualifying for CDDP treatmentresults showed that CBDCA plus RT and Cmab PLUSRT patient characteristics were: median age, 74 and 75 years old; 0-1 performance status, 90% and 100%; CBDCA plus RT's median follow-up time was 60.0 months, Cmab plus RT's median follow-up time was 53.6 months, the three-year positioning control rate was 56% to 58%, and the median progression-free survival was 42.7 to 11.6 monthsCBDCA PLUSRT is associated with more 3/4 levels of hematologic toxicity, including neutrophil reduction and platelet reduction, while Cmab plus RT is associated with more 3/4 levels of oral mucositis and radioactive dermatitisin general, the results show that CBDCA or Cmab as a systematic treatment performed at the same time as RT is a possible treatment option for LASCCHN patients who do not meet CDDP treatment conditions, but attention should be paid to hematotoxicity